Disease: Clinical Trials

14 trials for Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 terminated. 14 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Terminated 14
Phase 21Terminated 1

Follow Disease: new trials by email Literature Review of Disease trials Research Report on Disease

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
XEN496 - Epilepsy, Epilepsy in Children
Phase 3TerminatedXenon Pharmaceuticals Inc.82021-08-172025-02-14
Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:
Montelukast, placebo - Covid19, SARS (Disease)
Phase 3TerminatedFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina862021-08-112024-07-03
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
XEN496, Placebo - Epilepsy, Epilepsy in Children
Phase 3TerminatedXenon Pharmaceuticals Inc.82021-03-292024-08-23
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Synergo® RITE + MMC - Bladder Cancer, Bladder Neoplasm
Phase 3TerminatedMedical Enterprises Ltd.52019-04-042020-04-15
Mometasone vs Budesonide in CRS With Polyposis
Budesonide 0.5 MG/ML, Mometasone nasal spray - Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis
Phase 3TerminatedUniversité de Sherbrooke362017-05-012022-09-21
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Adrabetadex - Niemann-Pick Disease, Type C
Phase 2 / Phase 3TerminatedMandos LLC662015-12-232023-08-29
Rivaroxaban in Thrombotic Antiphospholipid Syndrome
Experimental: Rivaroxaban - Antiphospholipid Syndrome
Phase 3TerminatedUniversity of Padova1212014-12-012018-01-30
Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia
Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution - Diagnostic, Procedures and Surgeries on or Through Accessible Mucous Membranes
Phase 3TerminatedLannett Company, Inc.1592014-03-012017-05-12
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
GA101, Rituximab, Doxorubicin - Diffuse Large B Cell Lymphoma CD20 Positive
Phase 3TerminatedThe Lymphoma Academic Research Organisation6712012-09-012018-03-07
Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)
Tegeline® - Drug Hypersensitivity
Phase 3TerminatedUniversity Hospital, Rouen62008-01-012015-03-24
A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery
Dexmedetomidine, Placebo - Delirium
Phase 3TerminatedHospira, now a wholly owned subsidiary of Pfizer522007-04-012015-07-24
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Octreotide, 30 mg i.m. LAR formulation - Proliferative Diabetic Retinopathy
Phase 3TerminatedNovartis172003-12-012008-08-12
The DANTE Trial. A Randomized Study on Lung Cancer Screening With Low-Dose Spiral Computed Tomography
Spiral Computed Tomography - Lung Cancer
Phase 3TerminatedIstituto Clinico Humanitas24002001-06-012007-01-11
Canadian Pulmonary Embolism Diagnosis Study (CANPEDS)
Two diagnostic management strategies - Suspected Pulmonary Embolism, Deep Venous Thrombosis
Phase 3TerminatedHamilton Health Sciences Corporation11261998-08-012006-05-03

Narrower conditions

Nervous System Diseases (3)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Epilepsy (2)  ·  Epileptic Syndromes (2)  ·  Seizures (2)  ·  Syndrome (2)  ·  Thrombosis (2)  ·  Antiphospholipid Syndrome (1)  ·  COVID-19 (1)  ·  Cognitive Dysfunction (1)  ·  Deglutition Disorders (1)  ·  Delirium (1)  ·  Drug Hypersensitivity (1)

Broader conditions

Pathologic Processes (14)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Respiratory Tract Diseases (4)  ·  Signs and Symptoms (4)  ·  Immune System Diseases (3)  ·  Lung Diseases (3)  ·  Neoplasms (3)  ·  Neurologic Manifestations (3)  ·  Cardiovascular Diseases (2)  ·  Embolism and Thrombosis (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Lymphatic Diseases (2)  ·  Mental Disorders (2)  ·  Neoplasms by Site (2)

Interventions

ezogabine (2)  ·  2-Hydroxypropyl-beta-cyclodextrin (1)  ·  Bleomycin (1)  ·  Budesonide (1)  ·  Cocaine (1)  ·  Cyclodextrins (1)  ·  Cyclophosphamide (1)  ·  Dexmedetomidine (1)  ·  Doxorubicin (1)  ·  Mitomycin (1)  ·  Octreotide (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  Rivaroxaban (1)  ·  Solutions (1)

Sponsors

Xenon Pharmaceuticals Inc. (2)  ·  Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina (1)  ·  Hamilton Health Sciences Corporation (1)  ·  Hospira, now a wholly owned subsidiary of Pfizer (1)  ·  Istituto Clinico Humanitas (1)  ·  Lannett Company, Inc. (1)  ·  Mandos LLC (1)  ·  Medical Enterprises Ltd. (1)  ·  Novartis (1)  ·  The Lymphoma Academic Research Organisation (1)  ·  University Hospital, Rouen (1)  ·  University of Padova (1)  ·  Université de Sherbrooke (1)

Countries

United States (6)  ·  Australia (3)  ·  Belgium (3)  ·  France (3)  ·  Italy (3)  ·  Canada (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Germany (1)  ·  New Zealand (1)  ·  Singapore (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Agnes Y Lee, MD (1)  ·  Alexander G Turpie, MB (1)  ·  Betlem Salvador Gonzalez, PhD (1)  ·  Clive Kearon, MD, PhD (1)  ·  Francisco Mera Cordero, MD (1)  ·  Gianni Ravasi, MD (1)  ·  James Douketis, MD (1)  ·  Jeffrey I Weitz, MD (1)  ·  Jeffrey S Ginsberg, MD (1)  ·  Jesus Almeda Ortega, PhD (1)  ·  Mark A Crowther, MD (1)  ·  Michael A O'Donnell, MD (1)  ·  Michael Gent, DSc (1)

Results publications

PMID 17936405, PMID 30002145, PMID 33097974, PMID 33211799, PMID 34572728, PMID 34991703, PMID 37422199, PMID 37734837, PMID 40030008, PMID 40934736

NIH funding

2015 (1)